C5aR and C5L2 act in concert to balance immunometabolism in adipose tissue

Molecular and Cellular Endocrinology

Volumn 382, Issue 1, 2014, Pages 325-333

  Poursharifi, Pegah ^a,b   Lapointe, Marc ^a   Fisette, Alexandre ^a,b   Lu, Huiling ^a   Roy, Christian ^a,b   Munkonda, Mercedes Nancy ^a,b   Fairlie, David P ^c   Cianflone, Katherine ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Acylation Stimulating Protein C3adesArg; Adipose tissue; Complement C5a; Inflammation; Serpentine receptor

Indexed keywords

ACYLATION STIMULATING PROTEIN; CHEMOATTRACTANT; COMPLEMENT COMPONENT C5A RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR LIKE RECEPTOR 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; KERATINOCYTE CHEMOATTRACTANT; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN KINASE B; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CELL DIFFERENTIATION; CELL ISOLATION; CYTOKINE PRODUCTION; DIMERIZATION; GENE; GENE EXPRESSION; IMMUNE RESPONSE; IMMUNOREGULATION; INSULIN RELEASE; IRS1 GENE; MOUSE; NONHUMAN; PGC1 ALPHA GENE; PHOSPHOLIPID SYNTHESIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; TRIACYLGLYCEROL SYNTHESIS;

ACYLATION STIMULATING PROTEIN; ACYLATION STIMULATING PROTEIN/C3ADESARG; ADIPOSE TISSUE; ASP; C5AR-LIKE RECEPTOR 2; C5L2; COMPLEMENT C5A; G PROTEIN-COUPLED RECEPTOR; GPCR; INFLAMMATION; KC; KERATINOCYTE CHEMOATTRACTANT; MCP-1; MONOCYTE CHEMOATTRACTANT PROTEIN -1; SERPENTINE RECEPTOR; TGS; TRIGLYCERIDE SYNTHESIS;

3T3-L1 CELLS; ADIPOCYTES; ADIPOSE TISSUE; ANIMALS; COMPLEMENT C5A; INSULIN RESISTANCE; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MODELS, BIOLOGICAL; RECEPTOR, ANAPHYLATOXIN C5A; RECEPTORS, CHEMOKINE; SIGNAL TRANSDUCTION;

EID: 84887398726     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2013.10.019     Document Type: Article

References (48)

1. Baldo A., Sniderman A., St-luce S., Avramoglu R., Maslowska M., Hoang B., Monge J., Bell A., Mulay S., Cianflone K. The adipsin-acylation stimulating protein system and regulation of intracellular triglyceride synthesis. J. Clin. Invest. 1993, 92:1543-1547.
2. Bamberg C., Mackay C., Lee H., Zahra D., Jackson J., Lim Y., Whitfeld P., Craig S., Corsini E., Lu B., Gerard C., Gerard N. The C5a receptor (C5aR) C5L2 is a modulator of C5aR-mediated signal transduction. J. Biol. Chem. 2010, 285:7633-7644.
3. Braun L., Christophe T., Boulay F. Phosphorylation of key serine residues is required for internalization of the complement 5a (C5a) anaphylatoxin receptor via a beta-arrestin, dynamin, and clathrin-dependent pathway. J. Biol. Chem. 2003, 278:4277-4285.
4. Cain S., Monk P. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg(74). J. Biol. Chem. 2002, 277:7165-7169.
5. Casado V., Cortes A., Ciruela F., Mallol J., Ferre S., Lluis C., Canela E.I., Franco R. Old and new ways to calculate the affinity of agonists and antagonists interacting with G-protein-coupled monomeric and dimeric receptors: the receptor-dimer cooperativity index. Pharmacol. Ther. 2007, 116:343-354.
6. Chen N., Mirtsos C., Suh D., Lu Y., Lin W., McKerlie C., Lee T., Baribault H., Tian H., Yeh W. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007, 446:203-207.
7. Cianflone K., Sniderman A., Walsh M., Vu H., Gagnon J., Rodriguez M. Purification and characterization of acylation stimulating protein. J. Biol. Chem. 1989, 264:426-430.
8. Cianflone K., Xia Z., Chen L. Critical review of acylation-stimulating protein physiology in humans and rodents. Biochim. Biophys. Acta 2003, 1609:127-143.
9. Cui W., Paglialunga S., Kalant D., Lu H., Roy C., Laplante M., Deshaies Y., Cianflone K. Acylation-stimulating protein/C5L2-neutralizing antibodies alter triglyceride metabolism in vitro and in vivo. Am. J. Physiol. Endocrinol. Metab. 2007, 293:E1482-E1491.
10. Cui W., Lapointe M., Gauvreau D., Kalant D., Cianflone K. Recombinant C3adesArg/acylation stimulating protein (ASP) is highly bioactive: a critical evaluation of C5L2 binding and 3T3-L1 adipocyte activation. Mol. Immunol. 2009, 46:3207-3217.
11. Cui W., Simaan M., Laporte S., Lodge R., Cianflone K. C5a- and ASP-mediated C5L2 activation, endocytosis and recycling are lost in S323I-C5L2 mutation. Mol. Immunol. 2009, 46:3086-3098.
12. Damian M., Martin A., Mesnier D., Pin J.P., Baneres J.L. Asymmetric conformational changes in a GPCR dimer controlled by G-proteins. EMBO J. 2006, 25:5693-5702.
13. DeMartino J., Van Riper G., Siciliano S., Molineaux C., Konteatis Z., Rosen H., Springer M. The amino terminus of the human C5a receptor is required for high affinity C5a binding and for receptor activation by C5a but not C5a analogs. J. Biol. Chem. 1994, 269:14446-14450.
14. Durigutto P., Macor P., Ziller F., De Maso L., Fischetti F., Marzari R., Sblattero D., Tedesco F. Prevention of arthritis by locally synthesized recombinant antibody neutralizing complement component C5. PLoS One 2013, 8:e58696.
15. Finch A., Wong A., Paczkowski N., Wadi S., Craik D., Fairlie D., Taylor S. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J. Med. Chem. 1999, 42:1965-1974.
16. Fisette A., Munkonda M., Oikonomopoulou K., Paglialunga S., Lambris J., Cianflone K. C5L2 receptor disruption enhances the development of diet-induced insulin resistance in mice. Immunobiology 2013, 218:127-133.
17. Fonseca M.I., Ager R.R., Chu S.H., Yazan O., Sanderson S.D., LaFerla F.M., Taylor S.M., Woodruff T.M., Tenner A.J. Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J. Immunol. 2009, 183:1375-1383.
18. Gao H., Neff T., Guo R., Speyer C., Sarma J., Tomlins S., Man Y., Riedemann N., Hoesel L., Younkin E., Zetoune F., Ward P.A. Evidence for a functional role of the second C5a receptor C5L2. FASEB J. 2005, 19:1003-1005.
19. Gerard N., Lu B., Liu P., Craig S., Fujiwara Y., Okinaga S., Gerard C. An anti-inflammatory function for the complement anaphylatoxin C5a-binding protein, C5L2. J. Biol. Chem. 2005, 280:39677-39680.
20. Grailer J.J., Bosmann M., Ward P.A. Regulatory effects of C5a on IL-17A, IL-17F, and IL-23. Front. Immunol. 2013, 3:387.
21. Johswich K., Klos A. C5L2 - an anti-inflammatory molecule or a receptor for acylation stimulating protein (C3a-desArg)?. Adv. Exp. Med. Biol. 2007, 598:159-180.
22. Johswich K., Martin M., Thalmann J., Rheinheimer C., Monk P., Klos A. Ligand specificity of the anaphylatoxin C5L2 receptor and its regulation on myeloid and epithelial cell lines. J. Biol. Chem. 2006, 281:39088-39095.
23. Kalant D., Cain S., Maslowska M., Sniderman A., Cianflone K., Monk P. The chemoattractant receptor-like protein C5L2 binds the C3a des-Arg77/acylation-stimulating protein. J. Biol. Chem. 2003, 278:11123-11129.
24. Kalant D., MacLaren R., Cui W., Samanta R., Monk P., Laporte S., Cianflone K. C5L2 is a functional receptor for acylation-stimulating protein. J. Biol. Chem. 2005, 280:23936-23944.
25. Klos A., Tenner A., Johswich K., Ager R., Reis E., Kôhl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009, 46:2753-2766.
26. Kwan W.H., van der Touw W., Paz-Artal E., Li M.O., Heeger P.S. Signaling through C5a receptor and C3a receptor diminishes function of murine natural regulatory T cells. J. Exp. Med. 2013, 210:257-268.
27. Li K., Fazekasova H., Wang N., Peng Q., Sacks S.H., Lombardi G., Zhou W. Functional modulation of human monocytes derived DCs by anaphylatoxins C3a and C5a. Immunobiology 2012, 217:65-73.
28. Lim J., Iyer A., Suen J., Seow V., Reid R., Brown L., Fairlie D. C5aR and C3aR antagonists each inhibit diet-induced obesity, metabolic dysfunction, and adipocyte and macrophage signaling. FASEB J. 2013, 27:822-831.
29. MacLaren R., Cui W., Cianflone K. Adipokines and the immune system: an adipocentric view. Adv. Exp. Med. Biol. 2008, 632:1-21.
30. Maslowska M., Vu H., Phelis S., Sniderman A.D., Rhode B.M., Blank D., Cianflone K. Plasma acylation stimulating protein, adipsin and lipids in non-obese and obese populations. Eur. J. Clin. Invest. 1999, 29:679-686.
31. Maslowska M., Legakis H., Assadi F., Cianflone K. Targeting the signaling pathway of acylation stimulating protein. J. Lipid Res. 2006, 47:643-652.
32. Milligan G. G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. Br. J. Pharmacol. 2009, 158:5-14.
33. Monk P., Scola A., Madala P., Fairlie D. Function, structure and therapeutic potential of complement C5a receptors. Br. J. Pharmacol. 2007, 152:429-448.
34. Murray I., Parker R., Kirchgessner T., Tran J., Zhang Z., Westerlund J., Cianflone K. Functional bioactive recombinant acylation stimulating protein is distinct from C3a anaphylatoxin. J. Lipid Res. 1997, 38:2492-2501.
35. Nikolajczyk B., Jagannathan-Bogdan M., Denis G. The outliers become a stampede as immunometabolism reaches a tipping point. Immunol. Rev. 2012, 249:253-275.
36. Ohno M., Hirata T., Enomoto M., Araki T., Ishimaru H., Takahashi T. A putative chemoattractant receptor, C5L2, is expressed in granulocyte and immature dendritic cells, but not in mature dendritic cells. Mol. Immunol. 2000, 37:407-412.
37. Okinaga S., Slattery D., Humbles A., Zsengeller Z., Morteau O., Kinrade M., Brodbeck R., Krause J., Choe H., Gerard N., Gerard C. C5L2, a nonsignaling C5A binding protein. Biochemistry 2003, 42:9406-9415.
38. Paglialunga S., Schrauwen P., Roy C., Moonen-Kornips E., Lu H., Hesselink M., Deshaies Y., Richard D., Cianflone K. Reduced adipose tissue triglyceride synthesis and increased muscle fatty acid oxidation in C5L2 knockout mice. J. Endocrinol. 2007, 194:293-304.
39. Paglialunga S., Fisette A., Yan Y., Deshaies Y., Brouillette J., Pekna M., Cianflone K. Acylation-stimulating protein deficiency and altered adipose tissue in alternative complement pathway knockout mice. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E521-E529.
40. Pello O., Martinez-Munoz L., Parrillas V., Serrano A., Rodriguez-Frade J., Toro M., Lucas P., Monterrubio M., Martinez-A C., Mellado M. Ligand stabilization of CXCR4/delta-opioid receptor heterodimers reveals a mechanism for immune response regulation. Eur. J. Immunol. 2008, 38:537-549.
41. Poursharifi P., Lapointe M., Pétrin D., Devost D., Gauvreau D., Hébert T., Cianflone K. C5L2 and C5aR interaction in adipocytes and macrophages: insights into adipoimmunology. Cell. Signal. 2013, 25:910-918.
42. Rittirsch D., Flierl M., Nadeau B., Day D., Huber-Lang M., Mackay C., Zetoune F., Gerard N., Cianflone K., Kôhl J., Gerard C., Sarma J., Ward P. Functional roles for C5a receptors in sepsis. Nat. Med. 2008, 14:551-557.
43. Roy C., Paglialunga S., Fisette A., Schrauwen P., Moonen-Kornips E., St-Onge J., Hesselink M., Richard D., Joanisse D., Cianflone K. Shift in metabolic fuel in acylation-stimulating protein-deficient mice following a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E1051-E1059.
44. Roy C., Gupta A., Fisette A., Lapointe M., Poursharifi P., Richard D., Lu H., Lu B., Gerard N., Gerard C., Cianflone K. C5a receptor deficiency alters energy utilization and fat storage. PLoS One 2013, 8:e62531.
45. Schâffler A., Schôlmerich J. Innate immunity and adipose tissue biology. Trends Immunol. 2010, 31:228-235.
46. Schipper H., Prakken B., Kalkhoven E., Boes M. Adipose tissue-resident immune cells: key players in immunometabolism. Trends Endocrinol. Metab. 2012, 23:407-415.
47. Tom F., Gauvreau D., Lapointe M., Lu H., Poursharifi P., Luo X., Cianflone K. Differential chemoattractant response in adipocytes and macrophages to the action of acylation stimulating protein. Eur. J. Cell. Biol. 2013, 92:61-69.
48. Wong A., Finch A., Pierens G., Craik D., Taylor S., Fairlie D. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a. J. Med. Chem. 1998, 41:3417-3425.